Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 491Lung Neoplasms 208Adenocarcinoma of Lung 49Small Cell Lung Carcinoma 35Neoplasms 31Adenocarcinoma, Bronchiolo-Alveolar 25Neoplasm Metastasis 20Breast Neoplasms 20Ovarian Neoplasms 19Colorectal Neoplasms 16Carcinoma 14Squamous Cell Carcinoma of Head and Neck 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Melanoma 13Carcinoma, Ovarian Epithelial 12Stomach Neoplasms 11Carcinoma, Renal Cell 9Head and Neck Neoplasms 8Respiratory Tract Neoplasms 7Prostatic Neoplasms 7Pancreatic Neoplasms 7Endometrial Neoplasms 7Thoracic Neoplasms 6Pleural Effusion, Malignant 6Lung Diseases 6Esophageal Neoplasms 6Colonic Neoplasms 6Carcinoma, Squamous Cell 6Adenocarcinoma 6Non-Squamous Non-Small Cell Lung Cancer 5

Interventions

pembrolizumab 1Radiotherapy 1Paclitaxel 1Erlotinib Hydrochloride 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Clear Cell × Paclitaxel × Thoracic × Clear all
NCT00563784 2019-11-20

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 11 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Adenocarcinoma, Clear Cell, Carcinoma, Giant Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡